These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21914463)

  • 1. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
    Bosotti R; Carpinelli P; Healy S; Locatelli G; Cappella P; Lanfrancone L; Calogero R; Moll J; Isacchi A
    Gene; 2012 Feb; 494(2):202-8. PubMed ID: 21914463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
    Steeghs N; Eskens FA; Gelderblom H; Verweij J; Nortier JW; Ouwerkerk J; van Noort C; Mariani M; Spinelli R; Carpinelli P; Laffranchi B; de Jonge MJ
    J Clin Oncol; 2009 Oct; 27(30):5094-101. PubMed ID: 19770380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danusertib, an aurora kinase inhibitor.
    Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
    Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
    Fraedrich K; Schrader J; Ittrich H; Keller G; Gontarewicz A; Matzat V; Kromminga A; Pace A; Moll J; Bläker M; Lohse AW; Hörsch D; Brümmendorf TH; Benten D
    Clin Cancer Res; 2012 Sep; 18(17):4621-32. PubMed ID: 22753592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
    Zhang L; Zhang S
    J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
    Gontarewicz A; Brümmendorf TH
    Recent Results Cancer Res; 2010; 184():199-214. PubMed ID: 20072840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
    Steeghs N; Mathijssen RH; Wessels JA; de Graan AJ; van der Straaten T; Mariani M; Laffranchi B; Comis S; de Jonge MJ; Gelderblom H; Guchelaar HJ
    Invest New Drugs; 2011 Oct; 29(5):953-62. PubMed ID: 20182906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of danusertib's anticancer activity against melanoma by blockage of autophagy.
    Shang YY; Yu N; Xia L; Yu YY; Ma CM; Jiao YN; Li YF; Wang Y; Dang J; Li W
    Drug Deliv Transl Res; 2020 Feb; 10(1):136-145. PubMed ID: 31625025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora kinase inhibitors as anti-cancer therapy.
    Lok W; Klein RQ; Saif MW
    Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative effect of Aurora kinase targeting in mesothelioma.
    Crispi S; Fagliarone C; Biroccio A; D'Angelo C; Galati R; Sacchi A; Vincenzi B; Baldi A; Verdina A
    Lung Cancer; 2010 Dec; 70(3):271-9. PubMed ID: 20371132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways.
    Li M; Jung A; Ganswindt U; Marini P; Friedl A; Daniel PT; Lauber K; Jendrossek V; Belka C
    Biochem Pharmacol; 2010 Jan; 79(2):122-9. PubMed ID: 19686703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and biological evaluation of a novel aurora A kinase inhibitor.
    Sardon T; Cottin T; Xu J; Giannis A; Vernos I
    Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of danusertib, an Aurora kinase inhibitor, onto the cytotoxicity, cell cycle and apoptosis in pancreatic ductal adenocarcinoma cells.
    Kirbiyik IA; Ozcimen AA
    J Cancer Res Ther; 2021; 17(6):1419-1424. PubMed ID: 34916372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.
    Yang H; Burke T; Dempsey J; Diaz B; Collins E; Toth J; Beckmann R; Ye X
    FEBS Lett; 2005 Jun; 579(16):3385-91. PubMed ID: 15922328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2.
    Li J; Anderson MG; Tucker LA; Shen Y; Glaser KB; Shah OJ
    Cell Death Differ; 2009 Mar; 16(3):498-511. PubMed ID: 19079141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway.
    Soto-Cerrato V; Viñals F; Lambert JR; Pérez-Tomás R
    Biochem Pharmacol; 2007 Nov; 74(9):1340-9. PubMed ID: 17765876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
    Liu J; Hong J; Ahn KS; Go J; Han H; Park J; Kim D; Park H; Koh Y; Shin DY; Yoon SS
    Leuk Lymphoma; 2019 Oct; 60(10):2532-2540. PubMed ID: 30947576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A.
    Liu HS; Ke CS; Cheng HC; Huang CY; Su CL
    Mol Pharmacol; 2011 Oct; 80(4):638-46. PubMed ID: 21757545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and pyrazolo[3,4-b]pyridines for Aurora-A kinase inhibitors.
    Shi J; Xu G; Zhu W; Ye H; Yang S; Luo Y; Han J; Yang J; Li R; Wei Y; Chen L
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4273-8. PubMed ID: 20621733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma.
    Barzon L; Gnatta E; Castagliuolo I; Trevisan M; Moretti F; Pontecorvi A; Boscaro M; Palù G
    Cancer Gene Ther; 2005 Apr; 12(4):381-8. PubMed ID: 15650765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.